At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 178 enrolled
Drug / intervention
Pazopanib Hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
In Brief
A Phase 2 clinical trial evaluating Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, and 1 other intervention for Adult Liposarcoma and 6 related conditions. Completed, enrolled 178 participants across 8 sites.
Detailed Summary
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Liposarcoma, Recurrent Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma
CountriesUnited States
CollaboratorsGlaxoSmithKline, National Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartMar 2015
Primary CompletionApr 2018
Study CompletionOct 2021
TodayJul 2026
First PostedFeb 6, 2015
Enrollment StartMar 21, 2015
Primary CompletionApr 27, 2018
Study CompletionOct 12, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.4 years ago
Interventions
Pazopanib Hydrochloridedrug
Given PO
Oral Topotecan Hydrochloridedrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies